Abstract
Objective: Blood product transfusion is one of the most commonly used medical interventions worldwide. However, transfusion-related adverse events (TRAEs) can cause morbidity and rarely even mortality in patients. For this reason, hemovigilance studies have recently gained importance in terms of safe and effective implementation of transfusion. Material and methods: Transfusion practices issued in the period of 2016-2023 were analyzed retrospectively. All TRAE including adverse reactions (AR) and adverse events (AE) were recorded. The impact of hemovigilance practices on the incidence of TRAE was analyzed by comparing the numbers and types of events between years. Results: 135506 blood products were used for a total of 45571 patients for a total of 8 years between 2016 and 2023. 172 adverse reactions (AR) were reported in 170 patients. The overall AR incidence was found to be 126.8 (/100000). The highest yearly AR rate was reported in 2018 with 168.04 (/100000). Since hemovigilance measures were tightened, a statistically significant decrease was recorded in ARs from the beginning of 2020 to date (p
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
